Spots Global Cancer Trial Database for huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Official Title: A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Study ID: NCT00620607
Interventions
Study Description
Brief Summary: To assess the response rate of huC242-DM4 given as an intravenous infusion to patients with metastatic or locally advanced gastric or gastroesophageal junction cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
